627 reports of this reaction
3.1% of all REMDESIVIR reports
#7 most reported adverse reaction
ASPARTATE AMINOTRANSFERASE INCREASED is the #7 most commonly reported adverse reaction for REMDESIVIR, manufactured by Gilead Sciences, Inc.. There are 627 FDA adverse event reports linking REMDESIVIR to ASPARTATE AMINOTRANSFERASE INCREASED. This represents approximately 3.1% of all 20,319 adverse event reports for this drug.
Patients taking REMDESIVIR who experience aspartate aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ASPARTATE AMINOTRANSFERASE INCREASED is moderately reported among REMDESIVIR users, representing a notable but not dominant share of adverse events.
In addition to aspartate aminotransferase increased, the following adverse reactions have been reported for REMDESIVIR:
The following drugs have also been linked to aspartate aminotransferase increased in FDA adverse event reports:
ASPARTATE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 627 FDA reports for REMDESIVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ASPARTATE AMINOTRANSFERASE INCREASED accounts for approximately 3.1% of all adverse event reports for REMDESIVIR, making it a notable side effect.
If you experience aspartate aminotransferase increased while taking REMDESIVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.